Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

58
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
58
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

67
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
67
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

55
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
55
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

531
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
531
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

404
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
404
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

69
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
69

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Let there be light - when it's needed.

European journal of preventive cardiology·2026
Same author

SCI NutriTool: Development and Validation of a Questionnaire to Assess Non-Adherence to the Healthy Food Pyramid in Individuals with Spinal Cord Injury in Switzerland.

Nutrients·2026
Same author

Insomnia Symptoms in a Swiss Population-Based Cohort: Prevalence, Clinical Correlates and Polysomnographic Alterations.

Journal of sleep research·2026
Same author

Association of acylcarnitine species and diabetes incidence in a population-based apparently healthy cohort.

Cardiovascular diabetology. Endocrinology reports·2026
Same author

Association of Acylcarnitine Species and Anthropometry Markers in a Population-Based Apparently Healthy Cohort.

Metabolites·2026
Same author

Plasma soluble TREM-1 and risk of cardiovascular disease in the population. Results from the Paris Prospective Study III and the CoLaus|PsyCoLaus.

European journal of preventive cardiology·2026

Related Experiment Video

Updated: Nov 11, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.9K

Polypill eligibility and equivalent intake in a Swiss population-based study.

Julien Castioni1, Nazanin Abolhassani2, Peter Vollenweider1

  • 1Department of Medicine, Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Scientific Reports
|March 26, 2021
PubMed
Summary

A large portion of the Swiss population is eligible for polypills to manage cardiovascular disease (CVD). However, only one-third of eligible individuals use polypill equivalents, a proportion that remained unchanged over time.

More Related Videos

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.6K
Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography
03:47

Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography

Published on: November 1, 2024

316

Related Experiment Videos

Last Updated: Nov 11, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.9K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.6K
Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography
03:47

Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography

Published on: November 1, 2024

316

Area of Science:

  • Cardiovascular Disease Research
  • Public Health Policy
  • Pharmacological Interventions

Background:

  • The polypill is a strategy for cardiovascular disease (CVD) management.
  • Its potential benefit for the Swiss population remains unquantified.
  • Understanding polypill uptake is crucial for public health initiatives.

Purpose of the Study:

  • To determine the prevalence of polypill eligibility and current polypill equivalent use in Switzerland.
  • To identify factors influencing polypill equivalent intake in a population-based cohort.

Main Methods:

  • Analysis of data from a prospective population-based study in Lausanne, Switzerland (2009-2017).
  • Inclusion of participants aged 40-80 years across two follow-up periods.
  • Definition of polypill eligibility based on high CVD risk (SCORE equation ≥5%) or existing CVD.
  • Definition of polypill equivalents as combinations of statin, antihypertensives, and/or aspirin.

Main Results:

  • Polypill eligibility was 20.6% and 27.7% in the first and second follow-ups, respectively.
  • Approximately one-third of eligible individuals (29.5% and 30.4%) used polypill equivalents.
  • Male gender, age over 70, and smoking were associated with higher polypill equivalent use.
  • No significant change in the proportion of eligible individuals using polypill equivalents was observed between the two periods.

Conclusions:

  • A substantial segment of the Swiss population is eligible for polypill therapy for CVD prevention.
  • Current uptake of polypill equivalents remains low, with only one-third of eligible individuals benefiting.
  • Determinants of use include male gender, older age, and smoking status, highlighting potential targets for intervention.